Literature DB >> 15084117

Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles.

Ramani R Ranatunge1, Michael Augustyniak, Upul K Bandarage, Richard A Earl, James L Ellis, David S Garvey, David R Janero, L Gordon Letts, Allison M Martino, Madhavi G Murty, Stewart K Richardson, Joseph D Schroeder, Matthew J Shumway, S William Tam, A Mark Trocha, Delano V Young.   

Abstract

The synthesis of a series of novel pyrazoles containing a nitrate (ONO(2)) moiety as a nitric oxide (NO)-donor functionality is reported. Their COX-1 and COX-2 inhibitory activities in human whole blood are profiled. Our data demonstrate that pyrazole ring substituents play an important role in COX-2 selective inhibition, such that a cycloalkyl pyrazole (6b) was found to be a potent and selective COX-2 inhibitor. Other modifications at the 3 position of the central pyrazole ring (17b, 23b, 26b-I) enhanced COX-2 inhibitory potency. Among the pyrazoles synthesized, the oxime (23b) was identified as the most potent COX-2 selective inhibitor. Accordingly, 23b was profiled pharmacologically in the rat after oral administration and shown to possess potent antiinflammatory activity in the carrageenan-induced air-pouch model and less gastric toxicity than a standard COX-2 inhibitor when administered with background aspirin treatment. We suggest that the enhanced gastric tolerance of an NO-donor COX-2 selective inhibitor has the potential to augment the clinical profile of this drug class.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15084117     DOI: 10.1021/jm030276s

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines.

Authors:  Claudia Bocca; Francesca Bozzo; Andrea Bassignana; Antonella Miglietta
Journal:  Mol Cell Biochem       Date:  2010-12-08       Impact factor: 3.396

2.  A novel nitro-oxy substituted analogue of rofecoxib reduces human colon cancer cell growth.

Authors:  Claudia Bocca; Francesca Bozzo; Monica Ievolella; Antonella Miglietta
Journal:  Mol Cell Biochem       Date:  2011-10-15       Impact factor: 3.396

3.  NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor.

Authors:  James L Ellis; Michael E Augustyniak; Edward D Cochran; Richard A Earl; David S Garvey; Laura J Gordon; David R Janero; Subhash P Khanapure; L Gordon Letts; Terry L Melim; Madhavi G Murty; David J Schwalb; Matthew J Shumway; William M Selig; A Mark Trocha; Delano V Young; Irina S Zemtseva
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

4.  2-Methyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-one.

Authors:  Viktor Kettmann; Jan Světlík
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-04-08

5.  Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies.

Authors:  Marco Migliore; Damien Habrant; Oscar Sasso; Clara Albani; Sine Mandrup Bertozzi; Andrea Armirotti; Daniele Piomelli; Rita Scarpelli
Journal:  Eur J Med Chem       Date:  2015-12-23       Impact factor: 6.514

6.  (E)-1-Methyl-5-(3-methyl-4-chloro-phen-oxy)-3-trifluoro-meth-yl-1H-pyrazole-4-carbaldehyde O-acetyl-oxime.

Authors:  Hong Dai; Yan-Fei Shen; Jiao Chen; Hong-Lian Chen; Yong-Jun Shen
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-02-26

Review 7.  Anti-Inflammatory Drug Design Using a Molecular Hybridization Approach.

Authors:  Priscila Longhin Bosquesi; Thais Regina Ferreira Melo; Ednir Oliveira Vizioli; Jean Leandro Dos Santos; Man Chin Chung
Journal:  Pharmaceuticals (Basel)       Date:  2011-10-27

8.  Synthesis of thiophene and NO-curcuminoids for antiinflammatory and anti-cancer activities.

Authors:  Mahera M Ahmed; M Akram Khan; Kim Drummond Rainsford
Journal:  Molecules       Date:  2013-01-25       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.